Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398868 | 0.76 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL1892109 | 0.76 | METAP2 (0.39) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL2894575 | 0.75 | METAP2 (0.43) | METAP2METAP1NPY5RENPP1PTGDR2 | |
| SCHEMBL235437 | 0.67 | CACNA1H (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL7626867 | 0.67 | METAP2 (0.39) | METAP2METAP1NPY5RENPP1PTGDR2 | |
| SCHEMBL1235369 | 0.67 | METAP2 (0.37) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL1193887 | 0.66 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1PTGDR2 | |
| SCHEMBL3014791 | 0.66 | HSD17B10 (0.57) | METAP2METAP1NPY5R | |
| SCHEMBL3179127 | 0.66 | METAP2 (0.41) | METAP2METAP1NPY5RENPP1 | |
| SCHEMBL5440113 | 0.65 | KDM4C (0.47) | METAP2METAP1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | MERCK SHARP & DOHME CORP. | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, MTREX, CHIA | METAP2 741/4885METAP1 642/4885NPY5R 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.